AIM ImmunoTech Announces that the First Subject is enrolled in the Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca's Imfinzi for the Treatment of Late-Stage Pancreatic Cancer
OCALA - AIM ImmunoTech Inc. today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM's Ampligen with AstraZeneca's...
Source: marketscreener.com